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All forms of diabetes mellitus (DM) are characterized
by the loss of functional pancreatic b cell mass, lead-
ing to insufficient insulin secretion. Thus, identification
of novel approaches to protect and restore b cells
is essential for the development of DM therapies.
Mesencephalic astrocyte-derived neurotrophic fac-
tor (MANF) is an endoplasmic reticulum (ER)-stress-
inducible protein, but its physiological role in
mammals has remained obscure. We generated
MANF-deficient mice that strikingly develop severe
diabetes due to progressive postnatal reduction of
b cell mass, caused by decreased proliferation and
increased apoptosis. Additionally, we show that lack
of MANF in vivo in mouse leads to chronic unfolded
protein response (UPR) activation in pancreatic islets.
Importantly, MANF protein enhanced b cell prolif-
eration in vitro and overexpression of MANF in the
pancreas of diabetic mice enhanced b cell regen-
eration. We demonstrate that MANF specifically
promotes b cell proliferation and survival, thereby
constituting a therapeutic candidate for b cell protec-
tion and regeneration.
INTRODUCTION
Diabetes mellitus (DM) is a group of metabolic disorders charac-
terized by the loss of functional pancreatic b cell mass, leading to
insufficient insulin secretion (Talchai et al., 2012; Weir and Bon-
ner-Weir, 2013). Current diabetes therapies cannot prevent b cell
death or promote regeneration of remaining b cells and rarely
result in complete long-term metabolic normalization. Thus,
one of the main strategies in improving current DM therapy is
to define and validate novel approaches to protect and restore
b cell mass (Donath and Halban, 2004). In both rodents and366 Cell Reports 7, 366–375, April 24, 2014 ª2014 The Authorshumans, b cells are formed by neogenesis from endocrine
progenitor cells that proliferate extensively during the end of
embryogenesis and early postnatal period to reach the proper
adult b cell mass (Dhawan et al., 2007; Meier et al., 2008).
A number of cellular insults can disrupt protein folding and
cause accumulation of unfolded proteins, triggering endo-
plasmic reticulum (ER) stress, and, if prolonged, lead to ER-
stress-induced apoptosis (Szegezdi et al., 2006). Accumulation
and aggregation of unfolded proteins result in dissociation of
general ER stress chaperone GRP78/Bip from ER stress sensors
PERK, ATF6, and IRE1 and activation of downstream signaling
unfolded protein response (UPR) cascades, finally resulting in
decreased protein synthesis, increased protein folding capacity,
and degradation of misfolded proteins (Szegezdi et al., 2006;
Walter and Ron, 2011). Importantly, alterations in proteins
involved in ER stress and UPR are linked to diabetes in humans
and mice, suggesting that unresolved ER stress is involved in
the pathogenesis of b cell loss in type 1 and type 2 diabetes
(Dele´pine et al., 2000; Eizirik et al., 2008, 2013; Hetz, 2012).
MANF together with cerebral dopamine neurotrophic factor
forms a new, highly evolutionarily conserved protein family, effi-
ciently protecting and repairing midbrain dopaminergic neurons
in animal models of Parkinson’s disease and protecting cardiac
myocytes in myocardial infarction and cortical neurons against
ischemic stroke (Airavaara et al., 2009; Glembotski et al., 2012;
Hellman et al., 2011; Lindholm et al., 2007, 2008; Lindholm
and Saarma, 2010; Petrova et al., 2003; Voutilainen et al.,
2009). However, the cytoprotective mechanisms of MANF are
not known.
MANFmRNA and protein are widely expressed inmost human
and mouse organs with high levels in glandular cells of secretory
tissues such as pancreas and salivary gland (Lindholm et al.,
2008). Intracellularly, MANF localizes to the luminal ER, where
it interacts with the chaperone GRP78 and is secreted in
response to experimental ER stress in vitro (Apostolou et al.,
2008; Glembotski et al., 2012; Lindholm and Saarma, 2010; Miz-
obuchi et al., 2007). Thus, recent studies suggest that MANF is
an ER-stress-inducible protein for several cell populations.
Figure 1. Retarded Growth, Hyperglycemia,
and Hypoinsulinemia inManf-DeficientMice
(A) Schematic illustration of the wild-type Manf+/+
and mutant Manf/ loci. A b-galactosidase re-
porter cassette (b-gal), strong splicing acceptor
site (En2SA), exon (E), Frt (F)-site, LoxP (L)-
site, bAct::Neo; human b-actin promoter-driven
neomycin resistance gene. Arrowheads indicate
priming sites used in genotyping by PCR and in
RT-PCR.
(B) Growth curve of Manf+/+and Manf/ litter-
mates. Embryonic day (E) 18.5 to postnatal day (P)
2 (inset), n = 5–41, both sexes. P14–P56, n = 9–16,
only males.
(C) Ad libitum-fed blood glucose levels, n = 16–34.
(D) Blood glucose levels 30 min after glucose bolus
injection, n = 4–12.
(E) Serum insulin levels from ad libitum-fed mice,
n = 8–20.
(F) Blood glucose levels measured after insulin
injection, n = 5 per group.
(G) Serum insulin levels in P56 mice measured
30 min after glucose bolus injection, n = 4.
(H) In vitro insulin release from islets in response
to low glucose (1.67 mmol/l; G1.67), high glucose
(16.7 mmol/l; G16.7), and high glucose with
IBMX (1 mmol/l), normalized to islet DNA content
after 1 hr.
(I) In vitro glucose-stimulated insulin release
compared to total islet insulin content, n = islets
from five to six pancreases/group. Mean ± SEM,
*p < 0.05, **p < 0.01, ***p < 0.001 versus corre-
sponding control.
See also Figures S1 and S2.To understand the physiological role of MANF in vivo, we
generated MANF knockout mice (Manf/). Surprisingly,
Manf/ mice develop insulin-deficient diabetes due to pro-
gressive postnatal reduction of b cell mass caused by
decreased b cell proliferation and increased apoptosis. We
also demonstrate that pancreatic islets of Manf/ mice display
activation of UPR genes and proteins, implicating unresolved
ER stress as a primary cause of b cell failure. Consistently, re-
combinant MANF protein enhanced b cell proliferation in vitro.
Furthermore, after streptozotocin-induced diabetes, we found
enhanced b cell proliferation and reduced b cell death in theCell Reports 7, 366–regions of pancreas that had been trans-
duced to overexpress MANF. Our results
demonstrate that MANF specifically pro-
motes b cell proliferation and survival,
thereby constituting a promising thera-
peutic agent for b cell protection and
regeneration.
RESULTS
Loss of MANF in Mice Results in
Growth Retardation and Diabetes
To understand the physiological role
of MANF in vivo, we generated MANFknockout mice (Manf/) from an embryonic stem cell clone
MANF_D06 (EPD0162_3_D06; C57Bl/6N-Manf tm1a(KOMP)Wtsi),
containing a b-galactosidase reporter cassette with a strong
splice acceptor site inserted in the intron between exon 2
and exon 3 of the Manf gene, creating a constitutive null muta-
tion through splicing of exon 2 to the reporter cassette (Fig-
ure 1A). We confirmed that MANF full-length mRNA and protein
were not expressed in tissues of Manf/ mice (Figures S1A
and S1B). We found that MANF-deficient mice display progres-
sive gender-independent growth retardation (Figure 1B). In
addition, the body size and fat pad weights were significantly375, April 24, 2014 ª2014 The Authors 367
reduced in Manf/ male mice compared to wild-type (WT)
mice (Figures S1D–S1F). At 8–12 weeks of age, the health
of the mutant mice quickly deteriorated and the animals were
euthanized.
The blood glucose levels of ad libitum fed animals were within
normal range for Manf/ mice compared to wild-type Manf+/+
measured at postnatal day 1 (P1) and at P14 (Figure 1C). How-
ever, at P56, the Manf/ mice were severely hyperglycemic
(Figure 1C) and they consumed significantly more water than
Manf+/+ littermates (Figure S1G). Glucose tolerance test showed
a severely compromised glucose clearance compared to
Manf+/+mice already at P14 (Figure 1D). In addition, significantly
reduced levels of insulin were observed from sera of fed P28
Manf/mice compared toManf+/+ littermates, and at P56, insu-
lin was barely detectable (Figure 1E). Insulin tolerance test sug-
gested intact insulin sensitivity in the Manf/ mice (Figure 1F).
Circulating glucose-stimulated insulin levels were dramatically
decreased in P56Manf/mice (Figure 1G). Although remaining
islets derived from diabetic P35 Manf/ mice secreted less in-
sulin than WT islets after an overnight culture period (Figure 1H),
their capacity to secrete insulin relative to cellular insulin content
did not differ in response to glucose or glucose plus IBMX
(Figure 1I).
The diabetic phenotype was confirmed in independent condi-
tional PGKCre/+::Manfflox/flox(fl/fl) and pancreas-specific Pdx1Cre/+::
Manfflox/flox(fl/fl) mouse lines (Supplemental Results; Figures S2A–
S2I). Importantly, the diabetic phenotype was not observed
when MANF was deleted mainly in central nervous system
NestinCre/+:: Manf (fl/fl) mice, highlighting the indispensable role
of pancreatic MANF in regulation of b cell mass (Supplemental
Results; Figures S2J–S2K).
Postnatal Reduction in Pancreatic b Cell Mass in
Manf/ Mice Results from Decreased b Cell
Proliferation and Enhanced Apoptosis
Immunohistological analysis revealed a progressive postnatal
reduction in b cell mass, loss of islet architecture, and
decreased intensity of insulin immunoreactivity in Manf/
mice (Figures 2A–2G). At P56, most of the islet insulin-positive
b cells were lost from Manf/ pancreases (Figures 2E and
2F). Quantification of b cell mass revealed no difference be-
tween genotypes at embryonic day 18.5 (E18.5), whereas
already by P1, the reduction in Manf/ pancreases was 50%
and by P56, 85% (Figure 2G). Proliferation is important for the
b cell expansion during late embryogenesis and in the neonatal
period to reach the proper b cell mass (Dhawan et al., 2007).
There were no differences between genotypes in the number
of proliferating (bromodeoxyuridine+ or Ki67+) insulin-positive
b cells quantified from pancreases at E18.5 (Figures 2H, S3A,
and S3B), but a significant reduction in Ki67+ b cells was
observed in P1 and P14 Manf / mice (Figure 2H). Importantly,
the number of proliferating exocrine acinar cells did not differ
between genotypes (Figure 2I). Quantification of TUNEL+ b cells
revealed increased b cell apoptosis in Manf/ pancreas at P14
and P56 that coincided with the reduction of b cell mass
(Figures 2J and S3C). Glucagon immunohistochemistry showed
a normal a cell mass, indicating that the phenotype is b cell spe-
cific (Figures S3D–S3J).368 Cell Reports 7, 366–375, April 24, 2014 ª2014 The AuthorsDespite Its Universal Expression Pattern, MANF
Deficiency Affects b Cells
Expression of MANF has previously been detected in several
tissues, including pancreatic acinar cells at E17 and in adult
pancreatic islet cells (Lindholm et al., 2008; Mizobuchi et al.,
2007). We studied in more detail the expression of MANF in
mouse pancreas by double immunohistochemistry with insulin
and MANF antibodies. High MANF expression was colocalized
with insulin-positive b cells in mouse islets (Figure S4B, arrow-
head). However, MANF-positive immunostaining was also de-
tected in exocrine acinar cells (Figure S4B, arrow). Importantly,
none to very weak background staining of MANF was de-
tected in Manf/ pancreas (Figure S4E). Similarly to expres-
sion in mouse, we detected MANF expression in the islets
and exocrine tissue of human adult pancreas tissue (Figures
S4G–S4I).
Consistent with progressively reduced b cell mass from P1
Manf/ pancreas, there was significantly reduced expression
of glucose transporter 2 (Glut2), insulin1/insulin2 (Ins1/2), and
Pdx1 and a trend toward reduced glucokinase (Gck) expression
in islets of P1 Manf/ mice (Figures 3B–3D). Importantly,
reduced expression of these b cell markers was not observed
in pancreases of E18.5 mice (Figure 3A). Along with other b
cell-specific genes, also MafA mRNA expression was signifi-
cantly reduced already in P1 Manf/ islets (Figures 3B–3D).
GLUT2 immunohistochemistry showed clearly reduced mem-
brane localization and expression of GLUT2 protein in P14 and
P56 Manf/ b cells (Figures 3E–3J). Taken together, our data
indicate that the timing of the progressive loss of b cell pheno-
type occurs postnatally in Manf/ islets.
Loss of MANF Results in Activated Endoplasmic
Reticulum Stress and Unfolded Protein Response
Pathways
We next investigated ER stress and UPR pathways in Manf/
E18.5 pancreases and isolated islets. Significantly higher levels
of Chop and spliced Xbp1, but not Atf4, Grp78, or Atf6a, were
observed already in E18.5 Manf/ pancreases compared to
WT (Figure 4A). There was a trend toward higher levels of Atf4,
Grp78,Chop, spliced Xbp1, andAtf6amRNA expression in islets
from P1Manf/mice compared to WT (Figure 4B). A significant
elevation of mRNA levels for Atf4, Grp78, Chop, and Atf6a was
found in the islets isolated from P14 Manf/ pancreases
compared to WT islets (Figure 4C). Taken together, our results
demonstrate that loss of b cell phenotype is preceded by upre-
gulation of genes in IRE1 pathway starting at E18.5 followed by
activation of PERK and ATF6 pathways (Figure 4F).
Furthermore, quantification of phosphorylated (p)eIF2a band
intensities in relation to total levels of (t)eIF2a by western blot
analysis revealed a higher level of phosphorylated eIF2a in
P14, P28, and P56 Manf/ islets (Figures 4D and 4E), demon-
strating that the PERK pathway was constitutively activated in
the postnatal Manf/ islets (Figure 4F).
Recombinant MANF Induces Proliferation of Pancreatic
b Cells In Vitro and In Vivo
We assessed whether recombinant human MANF protein could
directly affect mouse b cell proliferation in vitro. Compared to
Figure 2. Decline in b Cell Mass in Manf-Deficient Mice Is Caused by Reduced b Cell Proliferation and Increased b Cell Death
(A–F) Insulin immunohistochemistry on pancreas sections fromManf+/+ (A, C, and E) andManf/ (B, D, and F) animals at P1 (A and B), P14 (C and D), and P56
(E and F). Arrow in (F) points to b cell with reduced insulin staining. The scale bar represents 50 mm.
(G) Progressive reduction in b cell mass in Manf/ mice from P1, n = 5 per group.
(H) b cell proliferation assessed by Ki67 and insulin staining, n = 3–5 per group.
(I) Acinar cell proliferation assessed from Ki67-positive DAPI-stained nuclei from pancreatic exocrine tissue, n = 5 to 6 per group.
(J) Islet b cell death assed by TUNEL and insulin double-staining, n = 5 per group. Mean ± SEM, **p < 0.01, ***p < 0.001 versus corresponding control.
See also Figure S3.islets cultured without added growth factors, MANF significantly
increased b cell proliferation (Figure 5A). Importantly, MANF
together with placental lactogen (PL), a potent mitogen for b
cells, further increased the number of proliferating b cells.
Hence, extracellular MANF has a direct proliferative effect on
mouse b cells, implying the presence of a yet unidentified recep-
tor for MANF on the b cells capable of mediating intracellular
mitogenic signaling cascades.
Our observed effects of MANF removal from b cells in vivo and
exogenous recombinant MANF protein on b cells in vitro sug-
gested that MANFmight be therapeutic in a rodent model of dia-
betes. We therefore tested whether overexpression of MANF byintrapancreatic delivery of aMANF-expressing adenoassociated
virus serotype 6 (AAV6) in mice affects b cell proliferation
and survival after streptozotocin-induced b cell depletion. Three
weeks after AAV6-MANF or AAV6-RFP (a control red fluorescent
protein) administration, animals were injected with low-dose
streptozotocin (STZ) for 5 consecutive days to induce b cell defi-
ciency (Figure 5B). Robust, patchy expression of MANF or RFP
(Figures S5B, S5F, and S5J) was observed in islet b cells
(transduction efficiency 4.3% ± 1.5%) and exocrine tissue
(4.2% ± 1.5% cells transduced), confirming a successful deliv-
ery and overexpression of MANF and RFP. Consistent with
elevated blood glucose levels and reduced serum insulin levels,Cell Reports 7, 366–375, April 24, 2014 ª2014 The Authors 369
Figure 3. Expression of b Cell-Specific Genes Is Reduced in Manf/ Islets
Quantitative RT-PCR for mRNA levels of b cell-specific genesGlut2, Ins1/2,Pdx-1,MafA, andGck in E18.5 pancreases (A) and islets from P1 (B), P14 (C), and P56
(D) pancreases, n = 4–10 per group. Mean ± SEM, *p < 0.05, **p < 0.01, versus the corresponding control. GLUT2 immunohistochemistry of pancreas sections
from WT and Manf/ mice at P1 (E and H), P14 (F and I), and P56 (G and J); scale bar, 100 mm.
See also Figure S4.STZ-induced b cell loss was detected in the islets from mice
treated with STZ (Figures S5H and S5L–S5N).
Insulin immunoreactive islets were larger in the STZ-injected,
AAV6-MANF-treated pancreatic sections compared to the
AAV6-RFP-treated mice (Figures 5C, S5H, and S5L). Although370 Cell Reports 7, 366–375, April 24, 2014 ª2014 The Authorsthe blood glucose and insulin levels were comparable between
AAV6-MANF and AAV6-RFP STZ-injected groups, we found
a significantly higher b cell proliferation rate in the STZ-in-
jected, AAV6-MANF-treated groups compared to both the
buffer-injected (nonlesioned) AAV6-RFP and the STZ-injected
AAV6-RFP groups (Figures 5D, S5M, and S5N), demonstrating
that overexpression of MANF could enhance b cell proliferation
and regeneration in vivo. Importantly, we found no significant dif-
ference in the number of proliferating exocrine acinar cells be-
tween treatment groups, suggesting that the proliferative effect
of MANF was specific for endocrine pancreas (Figure 5E). Addi-
tionally, AAV6-MANF significantly protected against b cell death
compared to the AAV6-RFP STZ-injected group (Figure 5F).
Taken together, our results demonstrate that gene therapy using
MANF is able to induce b cell proliferation and regeneration
and protect b cells from apoptosis in an experimental diabetes
model.
DISCUSSION
In order to understand the physiological role of MANF in mam-
mals, we generated MANF-deficient mice. Surprisingly, MANF
deficiency in mice leads to a progressive loss of b cells, resulting
in diabetes mellitus due to reduced b cell proliferation and
enhanced b cell death. The severe diabetic phenotype of global
Manf/mice was unexpected because inactivation of MANF in
fruit fly and knockdown of Manf mRNA expression in zebrafish
causes a dopaminergic phenotype (Chen et al., 2012; Palgi
et al., 2009). Conditional removal of MANF specifically from the
pancreas in Pdx1Cre/+:: Manffl/fl mice leads to a diabetic pheno-
type similar to the global knockout mice. However, inactivation
of MANF by Nestin-Cre expression did not result in a diabetic
phenotype. In Nestin-Cre mice, Cre recombinase activity is de-
tected in the CNS by E11, in mesenchymal and epithelial cells
of the early pancreatic primordium, and in scattered acinar cells
of the exocrine pancreas in adults, but not in islet endocrine
cells (Delacour et al., 2004). Thus, our results obtained from con-
ditional removal of MANF strongly suggest that MANF produced
locally in the islets is important for the b cell proliferation and
survival.
Previous studies have shown that MANF is upregulated in ER
stress in vitro and can protect several cell populations from ER-
stress-induced cell death in vivo (Airavaara et al., 2009; Aposto-
lou et al., 2008; Glembotski et al., 2012; Voutilainen et al., 2009).
Interestingly, MANF protein level was also increased in the b cells
of diabetic Akita mice in which ER stress is caused by the accu-
mulation of proinsulin in the ER (Mizobuchi et al., 2007). Further-
more, MANF total knockdown in fruit fly embryos has revealed
increased expression of several genes involved in ER stress
and increased eIF2a phosphorylation (Palgi et al., 2012).
Here, we show that lack ofMANF in vivo leads to ER stress and
chronic UPR activation in pancreatic islets. The activation of
UPR is clearly evident already at E18.5 by increased expression
of spliced Xbp1 and Chop mRNA, followed by the upregulation
of the general ER stress marker Grp78 and genes in the PERK
and ATF6 pathways. Importantly, we found no difference in b
cell mass or in the number of proliferating b cells quantified
fromWT andManf/ pancreases at E18.5. Similarly, b cell-spe-
cific genes Glut2, Ins1/2, Pdx1, and Gck were not significantly
downregulated in Manf/ pancreas at E18.5, indicating that
ER stress precedes the impaired b cell function.
As MANF is widely expressed in several tissues, the question
arises why global MANF knockdown results in such a robustb cell phenotype. Increased phosphorylation of eIF2a that is
known to lead to a global decrease in mRNA translation initiation
is tolerated poorly by b cells (Cnop et al., 2007). In addition, pro-
longed ATF6 activation downregulates transcription factors
PDX1 andMAFA, both critical for promoting expression of insulin
and important for b cell function (Artner et al., 2010; Seo et al.,
2008). Thus, the current evidence suggests that UPR activation
detected already at E18.5 in Manf/ islets affects the expres-
sion of b cell-specific proteins, leading to decreased insulin
expression, reduced b cell proliferation, and increased b cell
death.
Several factors contributing to the regulation of b cell
mass, including insulin-like growth factors (IGF-I and IGF-II),
glucagon-like peptide-1, prolactin, growth hormone, and
placental lactogens, are potential therapeutic targets for expan-
sion of the human b cell mass (Tarabra et al., 2012). However,
therapeutic use of some of these hormones and growth factors
has been limited by the lack of specificity, stimulation of uncon-
trolled b cell growth, and adverse effects on b cell function.
Furthermore, knockdown studies have revealed that many of
these factors are not essential for physiological b cell expansion
and survival (Tarabra et al., 2012; Vasavada et al., 2006).
Recently, a potential specific growth factor for b cells, named be-
tatrophin (alias ANGPTL8), was identified (Yi et al., 2013). How-
ever, the finding that deletion of ANGPTL8 did not affect b cell
mass or glucose metabolism (Wang et al., 2013) indicates that
its physiological action on b cells is very different from MANF.
Here, we show that recombinant MANF is a potent stimulator
of b cell proliferation in vitro, constituting a protein with therapeu-
tic potential for stimulating b cell renewal. Additionally, our work
provides tools for finding the mechanism of MANF action by
identifying its receptor(s) and signaling pathways in b cells.
Our in vivo gene therapy experiment using AAV-6 MANF
showed that, despite low transduction efficiency (only 4% of
the b cells) of pancreatic cells, MANF promotes normal islet
morphology and specifically enhances b cell proliferation and
protects b cells in mice in an experimental diabetes model.
Future experiments using higher virus titers, longer MANF over-
expression, and different diabetic models are clearly needed to
validate the therapeutic potential of MANF.
The severe postnatal decline in b cell mass in theManf/mice
and our in vitro and in vivo data indicate thatMANFmay be one of
the most potent secreted growth factors for regulating both b
cell proliferation and for maintaining b cell mass in mice. Finally,
high MANF expression in human pancreas suggests that MANF
might have similar b cell mitogenic effects also in humans. Future
studies will evaluate the potential of MANF to protect and
regenerate functional b cells as a therapeutic agent for treating
diabetes.
EXPERIMENTAL PROCEDURES
Manf-Targeted ESC Clone
The targeted mouse embryonic stem cell (ESC) clone MANF_D06
(EPD0162_3_D06, C57Bl/6N-Manf tm1a(KOMP)Wtsi) was generated by the
trans-National Institutes of Health (NIH) Knockout Mouse Project (KOMP)
and obtained from the KOMP Repository (http://www.komp.org). Genetically
modified ESCs were aggregated with morula-stage preimplantation embryos
(ICR strain) at the GM mouse unit of University of Helsinki.Cell Reports 7, 366–375, April 24, 2014 ª2014 The Authors 371
Figure 4. Unfolded Protein Response Genes Are Upregulated, and EIF2a Protein Is Phosphorylated in Islets from MANF-Deficient Mice
(A–C) Quantitative real-time PCR analysis of UPR genes Atf4, Grp78, Chop, Xbp1s, Xbpt, and Atf6a inManf+/+andManf/ E18.5 pancreases (A) and islets from
P1 (B) and P14 (C) pancreases, n = 4–13 per genotype.
(D) Western blotting with indicated antibodies on islet lysates from P14, P28, and P56 mice. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
(E) Quantified intensities of western blot bands of phosphorylated (p)EIF2awas compared to total amount of (t)EIF2a and tEIF2a to intensities of GAPDH, n = islets
from two to three pancreases per genotype. Mean ± SEM, *p < 0.05 versus corresponding Manf+/+control.
(F) Analyzed ER stress pathways and UPR genes are indicated in red. Vertical arrow denotes increased and horizontal arrow unchanged expression inManf/
islets compared to WT animals. Upon accumulation and aggregation of unfolded proteins, GRP78 dissociates from ER stress receptors PERK, ATF6, and IRE1,
(legend continued on next page)
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Figure 5. MANF Rescues Islet Size and
Selectively Induces b Cell Proliferation
In Vitro and In Vivo
(A) MANF recombinant protein increases b cell
proliferation after 5 days in culture. Placental lac-
togen (PL), n = 5 wells per point.
(B) Time course of the in vivo experiment.
(C) Distribution of islet size in the AAV6-RFP-
Buffer, AAV6-RFP-STZ, and AAV6-MANF-STZ
animals. Each symbol in the graph represents one
islet, and average islet size per group is shown by
horizontal lines. n = 5–8 per group.
(D) b cell proliferation in AAV6-virus-injected,
nonlesioned, and STZ-treated mice assessed by
Ki67 and insulin double staining, n = 6 per group.
(E) Acinar cell proliferation in AAV6-virus-injected,
nondiabetic, and STZ-treated mice, n = 6 per
group. NS, not significant.
(F) Islet cell death assessed by TUNEL followed by
insulin staining, n = 5 to 6 per group. Mean ± SEM,
**p<0.01, ***p<0.001versuscorrespondingcontrol.
See also Figure S5.Animals
All experimental procedures involving mice were approved by the Finnish
Animal Ethics Committee of the State Provincial Office of Southern Finland.
Mice were maintained in pathogen-free facility with a 12 hr light/dark cycle
and unlimited access to food (Harlan; Teklad Global; 16% protein rodent
diet; 2916) and water. In all studies comparing Manf+/+ and Manf/ mice,
we used sex-matched siblings derived from crossings of Manf heterozygous
(Manf+/) animals in hybrid C57Bl6 3 ICR mixed background. The day of
vaginal plug was designated as E0.5. Age-matched NMRI male mice for the
in vivo MLD-STZ experiment were obtained from Harlan Teklan, UK. Pancre-
atic islets were isolated from age-matched 8-week-old C57Bl/6JRccHsd
(Harlan) female mice in b cell proliferation assay.
Genomic DNA Isolation and Genotyping
DNA was isolated from earmarks, and genotyping was carried out by PCR us-
ing primers described in Supplemental Experimental Procedures.
Islet Isolation and In Vitro Insulin Release
Pancreases frommice were treated with collagenase P digestion (Collagenase
P; Roche Diagnostics) followed by hand-picking of islets under a stereomicro-
scope (Miettinen et al., 2006). Human pancreatic tissue was obtained at au-
topsy at the Helsinki University Central Hospital, and isolated human islets
were received from Uppsala, Sweden through the European Consortium for
Islet Transplantation. In vitro insulin release assaywas performed as previously
described (Miettinen et al., 2006).activating downstream signaling UPR cascades. Phosphorylated PERK blocks global mRNA translation by p
ATF4 escapes eIF2a translational control and in turn induces transcription of proapoptotic gene,Chop. Active
chaperone genes such as Grp78 and Xbp1 and controls genes involved in the ER-associated degradation. A
Xbp1, generating spliced Xbp1 (Xbp1s), which when translated to a transcription factor activates genes fo
folding. Figure modified from Szegezdi et al. (2006).
Cell Reports 7, 366–3RNA Isolation, Reverse Transcription,
and Quantitative PCR
RNA isolation, reverse transcription, quantitative
PCR, and primers are described in Supplemental
Experimental Procedures.
Food and Water Intake and Energy
Expenditure
Feeding and drinking, energy expenditure (O2 con-
sumption and CO2 production using indirect calo-rimetry), respiratory exchange ratio, and locomotor activity were measured
using CLAMS monitoring system (Columbus Instruments) in 6-week-old
mice. For detailed description, see Supplemental Experimental Procedures.
Western Analysis
Western blot was performed according to standard protocols and as
described in the Supplemental Experimental Procedures.
Immunohistochemistry and Quantification of b and a Cell Mass and
Islet Size
Immunohistochemistry was performed according to standard procedures,
and b and a cell mass analysis and islet size measurements were performed
as described in the Supplemental Experimental Procedures.
Analysis of Blood Samples
Blood samples from mice were collected from the tail vein or terminal blood
from heart and assayed for glucose (Accucheck Aviva Glucometer; Roche
Diagnostics) and insulin (ultrasensitive mouse insulin ELISA; Crystal Chem).
For glucose challenge test, P14 mice were fasted for 1 hr and P56 mice 5 to
6 hr before animals were injected intraperitoneally (i.p.) with 2 g/kg bodyweight
of glucose (in 0.9% NaCl). Insulin tolerance test was performed on 2 hr-fasted
P42male mice by injection of 1U/kg i.p. insulin (diluted in 0.9% saline; Humulin
Regular; Eli Lilly) and monitoring of blood glucose levels from tail vein every
15 min for 60 min.hosphorylating eIF2a subunit. Transcription factor
ATF6 translocates to the nucleus, where it induces
ctivated IRE1a removes by splicing an intron from
r ER-associated decay and chaperons for protein
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AAV Vector Construction and In Vivo Administration of AAV Vectors
The construction of the AAV packaging plasmids, generation of AAV vectors,
and retrograde pancreatic duct injections were carried out as described in
Supplemental Experimental Procedures. Three weeks after AAV administra-
tion, AAV6-MANF and AAV6-RFP animals were injected on 5 consecutive
days with a low dose of streptozotocin (40 mg/kg/day, i.p., freshly dissolved
in 0.1 M citrate buffer [pH 4.5]).
In Vitro b Cell Proliferation Assay
Islets from female, virgin, 8-week-old mice were isolated as described above.
Equal numbers of islets per well were treated for 5 days with recombinant
human placental lactogen (500 ng/ml; Affiland) or recombinant human MANF
(100 ng/ml; Icosagen) or amixture of both. The relative numbers of proliferating
b cells were quantified from wells of five repeats per treatment (details in
Supplemental Experimental Procedures).
Statistical Analysis
Unless otherwise stated, significance of differences between groups was
analyzed by Student’s unpaired two-tailed t test using Microsoft Excel
software. Differences between more than two groups were calculated by
one-way ANOVA followed by appropriate post hoc test using SPSS PASW
Statistics 18 program. For statistical analysis of islet size distribution, we
used GraphPad Prism 5, data were subjected to Kruskal-Wallis one-way
ANOVA test, and differences were evaluated by Dunn’s Multiple Comparison
Test. Results are expressed as mean ± SEM. Results were considered signif-
icant at p < 0.05.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Results, Supplemental
Experimental Procedures, and five figures and can be found with this article
online at http://dx.doi.org/10.1016/j.celrep.2014.03.023.
ACKNOWLEDGMENTS
S. A˚kerberg, S. Wiss, and D. Howard are thanked for excellent technical assis-
tance. We thank Frank Grosvelt for CAG-Flp mice and Edgar Kramer for
Nestin-Cre mice. We acknowledge NIH KOMP for the MANF-targeted ESC
clone. M.L. was supported by grant no. 117044 and J.R. by grant no.
260030 from the Academy of Finland. This work was supported by grants
from the Commission of the European Union, collaborative project MOLPARK,
no. 400752; The Lundbeck Foundation, personal price Mart Saarma, 2009, no.
7519003; Sigrid Juse´lius Foundation no. 4701537; and the Juvenile Diabetes
Research Foundation no. 17-2013-410. University of Helsinki has filed a patent
application based on these data with M.L., T.D., E.P., P.L., J.R., and M.S. as
inventors. University of Helsinki owns intellectual property rights.
Received: November 18, 2013
Revised: February 12, 2014
Accepted: March 7, 2014
Published: April 10, 2014
REFERENCES
Airavaara, M., Shen, H., Kuo, C.C., Pera¨nen, J., Saarma, M., Hoffer, B., and
Wang, Y. (2009). Mesencephalic astrocyte-derived neurotrophic factor re-
duces ischemic brain injury and promotes behavioral recovery in rats.
J. Comp. Neurol. 515, 116–124.
Apostolou, A., Shen, Y., Liang, Y., Luo, J., and Fang, S. (2008). Armet, a UPR-
upregulated protein, inhibits cell proliferation and ER stress-induced cell
death. Exp. Cell Res. 314, 2454–2467.
Artner, I., Hang, Y., Mazur, M., Yamamoto, T., Guo, M., Lindner, J., Magnuson,
M.A., and Stein, R. (2010). MafA and MafB regulate genes critical to beta-cells
in a unique temporal manner. Diabetes 59, 2530–2539.374 Cell Reports 7, 366–375, April 24, 2014 ª2014 The AuthorsChen, Y.C., Sundvik, M., Rozov, S., Priyadarshini, M., and Panula, P. (2012).
MANF regulates dopaminergic neuron development in larval zebrafish. Dev.
Biol. 370, 237–249.
Cnop, M., Ladriere, L., Hekerman, P., Ortis, F., Cardozo, A.K., Dogusan, Z.,
Flamez, D., Boyce, M., Yuan, J., and Eizirik, D.L. (2007). Selective inhibition
of eukaryotic translation initiation factor 2 alpha dephosphorylation potentiates
fatty acid-induced endoplasmic reticulum stress and causes pancreatic beta-
cell dysfunction and apoptosis. J. Biol. Chem. 282, 3989–3997.
Delacour, A., Nepote, V., Trumpp, A., and Herrera, P.L. (2004). Nestin expres-
sion in pancreatic exocrine cell lineages. Mech. Dev. 121, 3–14.
Dele´pine,M., Nicolino,M.,Barrett, T.,Golamaully,M., Lathrop,G.M., andJulier,
C. (2000). EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is
mutated in patients with Wolcott-Rallison syndrome. Nat. Genet. 25, 406–409.
Dhawan, S., Georgia, S., and Bhushan, A. (2007). Formation and regeneration
of the endocrine pancreas. Curr. Opin. Cell Biol. 19, 634–645.
Donath, M.Y., and Halban, P.A. (2004). Decreased beta-cell mass in diabetes:
significance, mechanisms and therapeutic implications. Diabetologia 47,
581–589.
Eizirik, D.L., Cardozo, A.K., and Cnop, M. (2008). The role for endoplasmic
reticulum stress in diabetes mellitus. Endocr. Rev. 29, 42–61.
Eizirik, D.L., Miani, M., and Cardozo, A.K. (2013). Signalling danger: endo-
plasmic reticulum stress and the unfolded protein response in pancreatic islet
inflammation. Diabetologia 56, 234–241.
Glembotski, C.C., Thuerauf, D.J., Huang, C., Vekich, J.A., Gottlieb, R.A., and
Doroudgar,S. (2012).Mesencephalicastrocyte-derivedneurotrophic factorpro-
tects the heart from ischemic damage and is selectively secreted upon sarco/
endoplasmic reticulum calcium depletion. J. Biol. Chem. 287, 25893–25904.
Hellman, M., Aruma¨e, U., Yu, L.Y., Lindholm, P., Pera¨nen, J., Saarma, M., and
Permi, P. (2011). Mesencephalic astrocyte-derived neurotrophic factor
(MANF) has a unique mechanism to rescue apoptotic neurons. J. Biol.
Chem. 286, 2675–2680.
Hetz, C. (2012). The unfolded protein response: controlling cell fate decisions
under ER stress and beyond. Nat. Rev. Mol. Cell Biol. 13, 89–102.
Lindholm, P., and Saarma, M. (2010). Novel CDNF/MANF family of neurotro-
phic factors. Dev. Neurobiol. 70, 360–371.
Lindholm, P., Voutilainen, M.H., Laure´n, J., Pera¨nen, J., Leppa¨nen, V.M.,
Andressoo, J.O., Lindahl, M., Janhunen, S., Kalkkinen, N., Timmusk, T.,
et al. (2007). Novel neurotrophic factor CDNF protects and rescues midbrain
dopamine neurons in vivo. Nature 448, 73–77.
Lindholm, P., Pera¨nen, J., Andressoo, J.O., Kalkkinen, N., Kokaia, Z., Lindvall,
O., Timmusk, T., and Saarma, M. (2008). MANF is widely expressed in
mammalian tissues and differently regulated after ischemic and epileptic
insults in rodent brain. Mol. Cell. Neurosci. 39, 356–371.
Meier, J.J., Butler, A.E., Saisho, Y., Monchamp, T., Galasso, R., Bhushan, A.,
Rizza, R.A., and Butler, P.C. (2008). Beta-cell replication is the primary mech-
anism subserving the postnatal expansion of beta-cell mass in humans.
Diabetes 57, 1584–1594.
Miettinen, P.J., Ustinov, J., Ormio, P., Gao, R., Palgi, J., Hakonen, E., Juntti-
Berggren, L., Berggren, P.O., and Otonkoski, T. (2006). Downregulation of
EGF receptor signaling in pancreatic islets causes diabetes due to impaired
postnatal beta-cell growth. Diabetes 55, 3299–3308.
Mizobuchi, N., Hoseki, J., Kubota, H., Toyokuni, S., Nozaki, J., Naitoh, M., Koi-
zumi, A., and Nagata, K. (2007). ARMET is a soluble ER protein induced by
the unfolded protein response via ERSE-II element. Cell Struct. Funct. 32,
41–50.
Palgi, M., Lindstro¨m, R., Pera¨nen, J., Piepponen, T.P., Saarma, M., and
Heino, T.I. (2009). Evidence that DmMANF is an invertebrate neurotrophic
factor supporting dopaminergic neurons. Proc. Natl. Acad. Sci. USA 106,
2429–2434.
Palgi, M., Greco, D., Lindstro¨m, R., Auvinen, P., and Heino, T.I. (2012). Gene
expression analysis of Drosophilaa Manf mutants reveals perturbations in
membrane traffic and major metabolic changes. BMC Genomics 13, 134.
Petrova, P., Raibekas, A., Pevsner, J., Vigo, N., Anafi, M., Moore, M.K., Peaire,
A.E., Shridhar, V., Smith, D.I., Kelly, J., et al. (2003). MANF: a new mesence-
phalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic
neurons. J. Mol. Neurosci. 20, 173–188.
Seo, H.Y., Kim, Y.D., Lee, K.M., Min, A.K., Kim, M.K., Kim, H.S., Won, K.C.,
Park, J.Y., Lee, K.U., Choi, H.S., et al. (2008). Endoplasmic reticulum stress-
induced activation of activating transcription factor 6 decreases insulin gene
expression via up-regulation of orphan nuclear receptor small heterodimer
partner. Endocrinology 149, 3832–3841.
Szegezdi, E., Logue, S.E., Gorman, A.M., and Samali, A. (2006). Mediators
of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 7, 880–885.
Talchai, C., Xuan, S., Lin, H.V., Sussel, L., and Accili, D. (2012). Pancreatic b
cell dedifferentiation as a mechanism of diabetic b cell failure. Cell 150,
1223–1234.
Tarabra, E., Pelengaris, S., and Khan, M. (2012). A simple matter of life and
death-the trials of postnatal Beta-cell mass regulation. Int. J. Endocrinol.
2012, 516718.Vasavada, R.C., Gonzalez-Pertusa, J.A., Fujinaka, Y., Fiaschi-Taesch, N.,
Cozar-Castellano, I., and Garcia-Ocan˜a, A. (2006). Growth factors and beta
cell replication. Int. J. Biochem. Cell Biol. 38, 931–950.
Voutilainen, M.H., Ba¨ck, S., Po¨rsti, E., Toppinen, L., Lindgren, L., Lindholm, P.,
Pera¨nen, J., Saarma, M., and Tuominen, R.K. (2009). Mesencephalic astro-
cyte-derived neurotrophic factor is neurorestorative in rat model of Parkin-
son’s disease. J. Neurosci. 29, 9651–9659.
Walter, P., and Ron, D. (2011). The unfolded protein response: from stress
pathway to homeostatic regulation. Science 334, 1081–1086.
Wang, Y., Quagliarini, F., Gusarova, V., Gromada, J., Valenzuela, D.M., Cohen,
J.C., and Hobbs, H.H. (2013). Mice lacking ANGPTL8 (Betatrophin) manifest
disrupted triglyceride metabolism without impaired glucose homeostasis.
Proc. Natl. Acad. Sci. USA 110, 16109–16114.
Weir, G.C., and Bonner-Weir, S. (2013). Islet b cell mass in diabetes and how it
relates to function, birth, and death. Ann. N Y Acad. Sci. 1281, 92–105.
Yi, P., Park, J.S., andMelton, D.A. (2013). Betatrophin: a hormone that controls
pancreatic b cell proliferation. Cell 153, 747–758.Cell Reports 7, 366–375, April 24, 2014 ª2014 The Authors 375
